L'intérêt à découvert pour AnaptysBio donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de AnaptysBio. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

AnaptysBio (NASDAQ:ANAB) Stock, Rapport sur les intérêts à découvert

AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

AnaptysBio Inc

<h3>Gainers</h3>
<ul>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares moved upwards by 172.2% to $12.55 during Wednesday's pre-market session. The company's market cap stands at $407.5 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock rose 34.75% to $0.53. The company's market cap stands at $5.3 million. </li>
<li>Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) stock moved upwards by 34.18% to $31.01. The market value of their outstanding shares is at $2.7 billion. As per the news, the Q2 earnings report came out 4 days ago. </li>
<li>Synlogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBX#NASDAQ">SYBX</a>) stock increased by 17.3% to $1.7. The market value of their outstanding shares is at $19.8 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock moved upwards by 14.86% to $0.85. The company's market cap stands at $3.6 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares moved upwards by 14.71% to $2.65. The market value of their outstanding shares is at $7.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) shares declined by 67.0% to $8.05 during Wednesday's pre-market session. The market value of their outstanding shares is at $98.0 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares decreased by 66.41% to $0.43. The company's market cap stands at $17.7 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares declined by 36.51% to $14.66. The market value of their outstanding shares is at $446.0 million. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares declined by 33.88% to $0.2. </li>
<li>ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) stock declined by 28.24% to $3.33. The market value of their outstanding shares is at $2.3 billion. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock fell 26.93% to $0.46. The market value of their outstanding shares is at $3.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ANAB

BPTH

CADL

CLRB

HEPA

IBRX

MBRX

NIVF

PDCO

QTTB

SYBX

TFFP

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

AnaptysBio shares are trading lower after the company announced it will discontinue its ANB023 development after its Phase 2b trial in atopic dermatitis failed to meet its endpoints. Also, HC Wainwright & Co. downgraded the stock from Buy to Neutral.

On Wednesday, AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42436193/anaptys-announces-phase-2b-trial-of-anb032-a-btla-agonist-did-not-meet-primary-or-secondary-endpoi" rel="noreferrer noopener">(AD) or eczema</a>.
&#8220;While ANB032 was safe and well tolerated, we&#8217;re disappointed by these efficacy results in AD and will discontinue further investment in this asset. Moving forward, our resources and capital will be focused on the rest of our exciting autoimmune portfolio,&#8221; said Daniel Faga, president and chief executive officer of Anaptys.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39891711/anaptysbio-investigational-arthritis-drug-might-have-better-efficacy-profile-than-eli-lillys-anal" rel="noreferrer noopener">AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly&#8217;s: Analyst</a>
&#8220;We look forward to sharing for rosnilimab, a depleter and agonist targeting PD-1+ T cells, top-line Phase 2b rheumatoid arthritis data in February 2025 and top-line Phase 2 ulcerative colitis data in Q1 2026, followed by Phase 1b data from our two additional programs.&#8221;
The study enrolled 201 patients with a mean baseline EASI score of 27.3 in the U.S., Canada, Europe, Australia and New Zealand, who were either biologics naïve (n=168) or biologics experienced (n=33), defined as having received treatment with dupilumab or other IL-13 therapies.
Patients were randomized to receive either 100mg of subcutaneous ANB032 every four weeks (Q4W), 400mg every four weeks (Q4W), 400mg every two weeks (Q2W), or placebo for 12 weeks.
The primary and secondary endpoints were assessed at Week 14.
Regardless of prior treatment experience, ANB032 did not meet the primary endpoint of the proportion of patients who achieved at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI-75), or any of the secondary endpoints at Week 14, including EASI-90, mean change in baseline EASI or a 4-point reduction in itch severity versus placebo.
Absolute response rates on key endpoints in patients treated with ANB032 approached the minimum target product profile with durable off-drug responses; however, higher placebo rates outside of the historical norm, particularly in the U.S., were observed.
ANB032 was well tolerated across all doses, and no safety signals were observed.
Price Action: ANAB stock is down 36.3% at $14.72 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/12/42439950/dental-product-supplier-patterson-companies-goes-private-in-4-1-billion-deal" target="_blank" rel="noreferrer noopener">Dental Product Supplier Patterson Companies Goes Private In $4.1 Billion Deal</a></li>
</ul>

Biotech

News

Health Care

Trading Ideas

General

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

HC Wainwright &amp; Co. analyst Emily Bodnar downgrades AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) from Buy to Neutral.

Downgrades

Analyst Ratings

HC Wainwright & Co. Downgrades AnaptysBio to Neutral

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Anaptys Discontinues ANB032 Development After Phase 2b Trial In Atopic Dermatitis Fails To Meet Endpoints; Focus Shifts To Rosnilimab Data In Rheumatoid Arthritis Expected February 2025; Year-End Cash Of $415M Extends Runway Through 2027

Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $56.33, along with a high estimate of $90.00 and a low estimate of $33.00. This upward trend is apparent, with the current average reflecting a 3.99% increase from the previous average price target of $54.17.
<img src="https://www.benzinga.com/files/images/story/2024/1733162467_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of AnaptysBio among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$52.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AnaptysBio. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of AnaptysBio compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for AnaptysBio's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into AnaptysBio's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AnaptysBio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About AnaptysBio</h2>
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
<h3>AnaptysBio: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: AnaptysBio's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 804.67%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -109.44%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -69.71%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -7.14%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.2, AnaptysBio adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From AnaptysBio Analyst Ratings

AnaptysBio shares are trading lower after BTIG downgraded the stock from Buy to Neutral.

BTIG analyst Julian Harrison downgrades AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) from Buy to Neutral.

BTIG Downgrades AnaptysBio to Neutral

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Overweight and lowers the price target from $75 to $66.

Price Target

JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $66

HC Wainwright &amp; Co. analyst Emily Bodnar maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Buy and lowers the price target from $55 to $52.

HC Wainwright & Co. Maintains Buy on AnaptysBio, Lowers Price Target to $52

AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.65) by 30.91 percent. This is a 19.15 percent increase over losses of $(1.41) per share from the same period last year. The company reported quarterly sales of $30.02 million which beat the analyst consensus estimate of $6.87 million by 336.74 percent. This is a 804.67 percent increase over sales of $3.32 million the same period last year.

Earnings

Earnings Beats

AnaptysBio Q3 EPS $(1.14) Beats $(1.65) Estimate, Sales $30.02M Beat $6.87M Estimate

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Buy and maintains $55 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $55 Price Target

<h3>Gainers</h3>
<ul>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock moved upwards by 106.1% to $4.18 during Wednesday's regular session. The market value of their outstanding shares is at $4.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 51.76% to $0.63. The company's market cap stands at $9.3 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock rose 35.29% to $1.34. The company's market cap stands at $58.8 million. </li>
<li>Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) stock rose 33.25% to $53.46. The company's market cap stands at $2.4 billion. The company's, Q3 earnings came out today. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock increased by 32.83% to $14.27. The company's market cap stands at $309.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) shares rose 31.66% to $5.17. The company's market cap stands at $55.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock decreased by 37.0% to $0.2 during Wednesday's regular session. The company's market cap stands at $2.0 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) stock declined by 25.56% to $22.93. The company's market cap stands at $692.4 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares declined by 20.46% to $6.75. The market value of their outstanding shares is at $411.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) shares decreased by 20.14% to $24.36. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares declined by 15.32% to $10.98. The market value of their outstanding shares is at $613.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares decreased by 15.06% to $18.89. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

CALC

CRMD

CVRX

ENSC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

OMCL

OPCH

SAGE

THAR

12 Health Care Stocks Moving In Wednesday's Intraday Session

AnaptysBio shares are trading lower. UBS maintained a Hold rating on the stock.

UBS analyst Eliana Merle maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Neutral and raises the price target from $23 to $33.

UBS Maintains Neutral on AnaptysBio, Raises Price Target to $33

U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Wednesday.
Shares of O-I Glass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 adjusted EPS <a href="https://www.benzinga.com/quote/OI/analyst-ratings">guidance below estimates</a>.
O-I Glass reported quarterly losses of 4 cents per share which missed the analyst consensus estimate of 4 cents per share. The company reported quarterly sales of $1.700 which missed the analyst consensus estimate of $1.761 billion.
O-I Glass shares dipped 18.4% to $10.15 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares dipped 22.5% to $23.86 in pre-market trading.</li>
<li>Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) shares fell 18% to $82.40 in pre-market trading after the company reported issued weak guidance for the third quarter.</li>
<li>Wingstop Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) dipped 15.7% to $311.00 in pre-market trading following weak quarterly earnings.</li>
<li>Criteo S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) shares fell 15.1% to $36.21 in pre-market trading following weak quarterly sales.</li>
<li>Thryv Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) fell 13.7% to $15.80 in pre-market trading after the company priced its upsized $80 million public offering of 5,715,000 common shares at $14/share.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) declined 10.7% to $806.57 in pre-market trading after the company reported worse-than-expected third-quarter earnings and sales.</li>
<li>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares fell 8.6% to $152.00 after the company reported third-quarter financial results.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) fell 8.4% to $47.17 in pre-market trading after gaining around 9% on Tuesday.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41599928/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-for-october">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio For October</a></li>
</ul>

Pre-Market Outlook

Markets

CRTO

QRVO

THRY

WING

O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares increased by 21.6% to $0.5 during Wednesday's pre-market session. The company's market cap stands at $7.5 million. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) stock rose 18.32% to $4.65. The company's market cap stands at $49.9 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares increased by 18.27% to $3.3. The company's market cap stands at $16.5 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) stock increased by 15.52% to $34.0. The market value of their outstanding shares is at $1.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 15.38% to $1.95. The market value of their outstanding shares is at $117.4 million. </li>
<li>HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) shares increased by 14.47% to $4.27. The company's market cap stands at $42.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock fell 41.7% to $0.18 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.9 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares fell 21.43% to $24.2. The company's market cap stands at $730.8 million. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) stock decreased by 19.85% to $1.05. The market value of their outstanding shares is at $56.7 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock fell 14.31% to $0.42. The market value of their outstanding shares is at $27.0 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares declined by 13.65% to $0.95. The company's market cap stands at $23.9 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) shares fell 11.92% to $9.46. The market value of their outstanding shares is at $205.3 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATRC

GLYC

HOOK

MTNB

SPRO

Tempest Therapeutics, Inc. - Common Stock

TPST

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 21.4% to $0.5 during Wednesday's pre-market session. The company's market cap stands at $7.5 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) stock increased by 18.92% to $35.0. The company's market cap stands at $1.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) stock increased by 18.32% to $4.65. The market value of their outstanding shares is at $49.9 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock moved upwards by 18.27% to $3.3. The company's market cap stands at $16.5 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 15.38% to $1.95. The company's market cap stands at $117.4 million. </li>
<li>HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) stock rose 14.47% to $4.27. The company's market cap stands at $42.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares fell 42.2% to $0.18 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares decreased by 21.43% to $24.2. The market value of their outstanding shares is at $730.8 million. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares fell 19.12% to $1.06. The market value of their outstanding shares is at $57.2 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock declined by 15.94% to $0.41. The company's market cap stands at $26.5 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) stock declined by 14.13% to $0.94. The company's market cap stands at $23.8 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock fell 11.92% to $9.46. The company's market cap stands at $205.3 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AnaptysBio (ANAB – Research Report) received a Hold rating and price target from BTIG analyst Julian Harrison today. The company's shares closed ye...

AnaptysBio (ANAB) was downgraded to a Hold Rating at BTIG

08:25 EST AnaptysBio (ANAB) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...

AnaptysBio trading halted, news pending

AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studi...

AnaptysBio announces Phase 2b trial of ANB032 did not meet primary endpoint

09:00 EST AnaptysBio (ANAB) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. T...

AnaptysBio trading resumes

Anaptys scraps development of ANB032, stock plunges 33%

H.C. Wainwright analyst Emily Bodnar downgraded AnaptysBio (ANAB) to Neutral from Buy with a $19 price target Published first on TheFly – the ultim...

AnaptysBio downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded AnaptysBio (ANAB) to Neutral from Buy with a price target of $19, down from $52, after the company announced topline res...

H.C. Wainwright downgrades AnaptysBio after atopic dermatitis study disappoints

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Albertsons (ACI) terminated its merger...

Albertsons terminates Kroger deal, Macy's reports Q3 beat: Morning Buzz

In a report released today, Emily Bodnar from H.C. Wainwright downgraded AnaptysBio (ANAB – Research Report) to a Hold, with a price target of $19....

Hold Rating on AnaptysBio Amidst Setbacks in ANB032 and Rosnilimab Efficacy

TD Cowen analyst Joseph Thome maintained a Buy rating on AnaptysBio (ANAB – Research Report) today. The company's shares opened today at $14.32. Ac...

Comments

AnaptysBio

Intérêt court

AnaptysBio (NASDAQ:ANAB) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL